Interleukin-13 and its receptors in colorectal cancer (Review)

RU ZHOU¹*, SHIGUANG QIAN²*, XIAODONG GU¹, ZONGYOU CHEN¹ and JIANBIN XIANG¹

¹Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China; ²Department of Immunology and General Surgery, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Received May 05, 2013; Accepted July 08, 2013

DOI: 10.3892/br.2013.132

Abstract. Interleukin (IL)-13 is an immunoregulatory cytokine secreted by numerous immune cells. Its functions are similar to those of IL-4 and they share a common receptor. This cytokine has been included in recent studies on human tumors and malignant diseases, evoking a scientific interest to investigate the role of IL-13 and its receptors as novel biomarkers and targets for therapy. Colorectal cancer is one of the most common human malignancies, its prognosis is not promising and the efficacy of molecular-targeted therapy has not been established. This review summarizes the currently available data on the role of IL-13 and its receptors in colorectal cancer, including the signaling pathways involved in mediating the effects of IL-13, the role of IL-13 and/or its receptors in the prediction of cancer and several drugs targeting IL-13 or its receptors that are currently under evaluation.

Contents
1. Introduction
2. IL-13-related pathways in cancer surveillance
3. IL-13 in cancer prediction
4. Targeting IL-13 and its receptors in cancer treatment
5. Conclusion

1. Introduction

Interleukin (IL)-13 was identified in 1989 (1). Since then, scientists have extensively investigated its structure, biological characteristics and mechanisms of action. IL-13 exhibits a wide range of biological activities and potential clinical applications.

The location of the IL-13 gene is in close proximity to the IL-4 gene (2). IL-13 is produced by T and B cells, mast cells, basophils, natural killer and dendritic cells (3) and plays a key role in inflammation and immune responses (4). Over the last few years, the known effector functions of IL-13 were significantly expanded (5). This function may be attributed to the development of unique animal models that either promote or inhibit the activity of IL-13 and/or its related gene, including mice deficient in IL-4, IL-4 receptor (R), signal transducer and activator of transcription (STAT) 6 or IL-13, as well as IL-13 transgenic mice that overexpress IL-13 and mice simultaneously deficient in IL-4 and IL-13. In addition, novel IL-13 antagonists and neutralizing antibodies (Abs) have also been generated. The effector functions mediated by IL-13 include the regulation of gastrointestinal parasite expulsion, airway hyperresponsiveness, allergic inflammation, immunoglobulin E Ab production, mastocytosis, goblet cell hyperplasia, tissue eosinophilia, intracutaneous parasitism, tissue remodeling, fibrosis and tumor cell growth. Some of its effects are also associated with tumor invasion and metastasis.

The receptor components of IL-13 are similar to those of IL-4. This may explain their biological characteristics being similar in many respects. Type I IL-4R only binds IL-4, whereas type II IL-4R binds IL-4 and IL-13 (6). Type II IL-4R is composed of the IL-4Ra and IL-13Rα1 chains (7). The IL-4Ra chain binds IL-4 and the IL-13Rα1 chain binds IL-13 (8). IL-13Rα1 alone exhibits low affinity for IL-13; however, when IL-4Ra and IL-13Rα1 combine to form the type II IL-4R dimer, it binds IL-13 with high affinity (9) and the complex mediates signal transduction through the JAK/STAT6 pathway (10). Apart from IL-13Rα1, IL-13 has another cognate receptor, IL-13Rα2, which binds IL-13 with a markedly high affinity, although it lacks any significant cytoplasmic domain and, therefore, does not mediate signal transduction (11,12). It was reported that IL-13Rα2 may regulate IL-13 and IL-4 signal transduction through internalization of IL-13 (13) and that the extracellular domain of IL-13Rα2 may serve as a decoy receptor for IL-13 (14,15).

IL-13Rα2 is highly expressed in several human tumors. It was previously demonstrated that it may serve as a biomarker of cancer as well as a therapeutic target (16). The prognosis of colorectal cancer, one of the most common human malignancies, is not promising, particularly in cases with distant organ metastasis, although significant advances have been achieved by molecular-targeted therapy and immunotherapy. At present,
cetuximab and bevacizumab are the main molecular-targeted drugs used in the treatment of colorectal cancer. However, recent studies indicated that not all colorectal cancer patients benefit from cetuximab therapy. Therefore, there is a need for more effective molecular targets and other therapeutic approaches (17,18). IL-13Rα2 may be an important target of immunotherapy in colorectal cancer and recombinant IL-13Rα2 protein may also be used as an antitumor vaccine, which may provide novel strategies for the treatment of colorectal cancer.

2. IL-13-related pathways in cancer surveillance

As mentioned above, IL-13Rs share components with IL-4Rs. Based on previous experiments conducted on colon carcinoma cell lines, IL-4 and IL-13 also share numerous signaling events. The ligation of IL-13 and IL-4R2 leads to rapid phosphorylation of three out of the four members of the Janus family of kinases (JAKs). Murata et al demonstrated that, within 1 min of activation, JAK2 was phosphorylated, with a peak at 10 min. IL-13 also promoted the phosphorylation of insulin response substrate-1, IL-4R p140, JAK1 and tyrosine kinase 2, but not that of JAK3 kinase. IL-4 also stimulates these kinases and substrates; however, it does not include JAK3 activation in its signaling in colon cancer cell lines. IL-4 and IL-13 induce the phosphorylation of STAT6, but not that of STAT1, STAT3 or STAT5. Data from that study suggested that IL-13 utilizes IL-4R and its signaling pathways and JAK2 may play an important role in the function of IL-4R and IL-13R in colon cancer cells (19). Kawakami et al (11) demonstrated that IL-13 did not activate STAT6 in IL-13Rα2-transfected cells, although it efficiently induced activation of the STAT6 protein in cells transfected with the IL-13Rα1 and IL-4Rα chains, whereas transfection with the IL-13Rα2 chain inhibited this activation (11). It has been generally accepted that chronic inflammation in ulcerative colitis is a significant risk factor for colorectal cancer. IL-13 is elevated in the ulcerative colitis mucosa and may induce deregulated signaling in neighboring intestinal epithelial cells; therefore, IL-13 may be considered a tumorigenic cytokine. In addition, IL-13Rα2 as a decoy receptor may also participate in modulating the balance and intensity of the signaling pathways initiated in ulcerative colitis and colorectal cancer (20).

IL-13-associated pathways are also involved in the development of other tumors. For example, Fujisawa et al (21) assessed cell invasion and protease activity in ovarian tumor cell lines that overexpress or are deficient in IL-13Rα2 and observed that IL-13 treatment significantly augmented cell invasion and enzyme activities in IL-13Rα2-positive but not in IL-13Rα2-negative cells in vitro. Mechanistically, IL-13 enhances the extracellular-signal-regulated kinase (ERK) 1/2, transcription factor AP-1 and matrix metalloproteinase (MMP) activities in IL-13Rα2-positive but not in IL-13Rα2-negative cells. By contrast, other signaling pathways, such as the insulin receptor substrate-1 and -2, phosphoinositide 3-kinase and AKT pathways are involved in IL-13 signaling in ovarian cancer cell lines. This was confirmed by the fact that highly specific inhibitors for MMP and AP-1 efficiently inhibited invasion and protease activities in IL-13Rα2-positive cells without affecting the basal level invasion and protease activities in vitro (22).

IL-13Rα2 has been widely recognized to be a secreted receptor that is devoid of signaling activity and functions only as a decoy receptor that delays signaling via IL-13Rα1. An important role of IL-13 signaling via IL-13Rα2 may be in tumor immune surveillance. Thus, relevant studies demonstrated that NKT cells stimulated by tumor antigens produce IL-13, which subsequently acts on Gr-1+ cells to induce the expression of transforming growth factor-β1 (TGF-β1); the latter then inhibits CD8+ T cells involved in tumor immune surveillance (23).

3. IL-13 in cancer prediction

Considering that cytokines are the key components in the inflammatory microenvironment, a better understanding of colorectal cancer at the molecular level may provide important tools for genetic screening in high-risk groups. A proinflammatory genotype is positively associated with colorectal adenoma, a precursor of colorectal cancer. In a previous study, an analysis of the IL-13 gene with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was conducted on a Polish population comprising 150 cancer patients and 170 healthy subjects. The results of that study suggested the possibility of an association between IL-13 gene polymorphism and colorectal cancer risk (24). Gunter et al (25) investigated the association of colorectal adenoma with 19 single-nucleotide polymorphisms in a range of important proinflammatory cytokines (IL-1B, IL-6, IL-8, TNF and LTA), anti-inflammatory cytokines (IL-4, IL-10 and IL-13) and the inflammation-related genes PTGS2 and PPARG in a case-control study of risk factors for colorectal polyps. The exploratory data obtained from that study provided evidence that polymorphic variations in genes that regulate inflammation may affect the risk for colorectal adenoma (25).

Inflammatory mediators are also of considerable interest as potential therapeutic targets in various types of cancer. IL-4Rα protein expression has been observed in human colon adenocarcinomas (26). In order to determine the role of IL-4Rα in colonic tumorigenesis, human and murine colon tumor cell lines expressing IL-4Rα were investigated. Treatment with exogenous ligands resulted in dose-dependent increases in proliferation. Mice with global deletion of IL-4Rα developed significantly fewer and smaller tumors. A systemic blockade of IL-4 and IL-4Rα interactions achieved similar results, suggesting that IL-4Rα ligation may contribute to tumor formation in mouse models (27).

A flow cytometric analysis revealed that monoclonal antibodies (mAbs) directed against E-cadherin and carcinoembryonic antigen (CEA) inhibited Colo 205 cell-cell adhesion. IL-4 significantly inhibited the expression of E-cadherin and CEA (26) and IL-13 inhibited colon cancer cell-cell adhesion. These results suggested that IL-4 and IL-13 inhibit colon cancer cell-cell adhesion by downregulating the expression of the adhesion molecules E-cadherin and CEA. In an animal model of human ovarian cancer, IL-13Rα2-positive tumors metastasized to the lymph nodes and peritoneum earlier during the course of the disease compared to IL-13Rα2-negative tumors. Of note, the IL-13Rα2-positive tumor-bearing mice died earlier compared to the mice with IL-13Rα2-negative tumors. Intraperitoneal injection of IL-13 further shortened
the survival of IL-13Rα2-positive tumor-bearing mice compared to IL-13Rα2-negative ones. IL-13Rα2-positive tumors and lymph node metastasis were associated with higher levels of MMPs and ERK1/2 expression compared to IL-13Rα2-negative tumors (23).

In a mouse model with a conditional deletion of TGF-β signaling in the neurons, 35% of the mice developed spontaneous squamous cell carcinomas. Transplantation of these tumors into athymic nude mice resulted in 62% tumorigenicity. A total of 33% of the tumors expressed the IL-13Rα2 chain (30).

4. Targeting IL-13 and its receptors in cancer treatment

The studies on IL-13 and IL-13-related receptors as therapeutic targets have been mainly focused on asthma and allergic diseases (27,28,29,31,32) with substantial achievements (Table I).

The immunotherapeutic approaches including cancer therapeutic vaccines targeting specific tumor-associated antigens are currently at various stages of development. The IL-13Rα2-directed cancer vaccine may be one of the most promising approaches to tumor immunotherapy, due to the selective expression of IL-13Rα2 in various solid tumor types and its absence in normal tissues. Nakashima et al (33) provided experimental evidence that the IL-13Rα2 chain was a functional component of an IL-13R system that promotes binding and internalization of the ligand. In addition, the IL-13Rα2 chain interacts with the IL-4Rα chains to inhibit the effect of IL-13 on STAT6 activation. IL-13Rα2 is not commonly expressed by normal immune and non-immune cells. These observations suggested that IL-13Rα2 is a potential target for receptor-directed immunotherapy or gene cancer therapy.

The studies on IL-13Rα2-related cancer treatment have been mainly performed on brain tumors. Hsi et al (34) knocked down IL-13Rα2 with short interfering RNA and markedly promoted tumor cell apoptosis and reduced glioblastoma multiforme tumor growth in vivo. The authors of that study identified a mechanism for eliminating the blockade of endogenous IL-13 signaling to promote tumor cell apoptosis. This targeting of IL-13Rα2 may be a novel approach to pharmacological intervention in brain tumors (34). A previous USA study (35) demonstrated that IL-13Rα2 was expressed by glioma stem-like cancer-initiating cells and differentiated tumor populations, rendering them targetable by IL-13Rα2-specific human CD8+ cytotoxic T cells (CTLs) [IL-13-zetakine+ CTLs (36). Wang et al synthesized IL-13 cDNA de novo by PCR, the cDNA was ligated into the plasmid vector and the T cells were transfected. This receptor recognized IL-13Rα2 and initiated cytolytic killing. It also incorporated a point mutation in the IL-13 ligand domain for preferential binding to IL-13Rα2 and reduced affinity to IL-13Rα1. Moreover, in an ovarian cancer animal model, IL-13Rα2 was shown to be involved in cancer metastasis through the activation of ERK/AP-1 pathway. Therefore, targeting IL-13Rα2 may not only directly kill primary tumors but also prevent cancer metastasis (23).

Although there is no direct evidence supporting the use of IL-13Rα2 in the treatment of colorectal cancer, the IL-13 regulatory pathway of tumor immune surveillance appeared to be active in a murine colon carcinoma lung metastasis model, in which tumor growth was partially inhibited in mice treated with an IL-13 inhibitor (5). A previous study conducted by Sinha et al also supported IL-4Rα as a therapeutic target in colon cancer (26). Although TGF-β inhibition enhanced antitumor immunity mediated by CD8+ T cells in several tumor models, anti-TGF-β mAb alone did not exhibit any antitumor effects. Experimental data provided by Shun et al indicated that anti-TGF-β enhanced the efficacy of a prophylactic vaccine in normal individuals, despite the absence of the elevated TGF-β levels observed in cancer patients (27).

In August, 2012, a novel mAb against IL-13Rα2, which competes with IL-13 for binding to IL-13Rα2 with high specificity and affinity, was generated and characterized (35). Therefore, studies assessing the therapeutic and diagnostic properties of this mAb in tumors are possible in the future. IL-13 may also be a potential predictive marker for cancer treatment, since the biological basis of tumor response to radiotherapy (RT) and chemotherapy (CT) is associated not only with the tumor and its microenvironment, but also with the host genetic background. The genetic polymorphisms are potential prognostic factors in several types of cancer. A previous study (37) that investigated a total of 128 SNPs distributed over 76 genes, demonstrated that IL-13 rs1800925 polymorphism is an independent predictive marker of the response to preoperative RT-CT in rectal cancer. Such markers may help discriminate rectal cancer patients who may benefit from neoadjuvant RT-CT from those who are candidates for targeted therapy (cetuximab or bevacizumab). Identification of IL-13 rs1800925 may allow personalization of rectal cancer therapy with a single blood sample test.

5. Conclusion

The advances in cancer treatment research are currently focused on the identification of new targets and the corresponding targeting drugs. However, the majority of these drugs did not withstand the test of time and repeated verification. The environment and signal transduction pathways in the human body are complex network systems and the various foreign interventions are mutually influential. In traditional chemotherapy, the key mechanistic step may be ultimately identified as blocking a signaling pathway, inhibiting the expression of a

<table>
<thead>
<tr>
<th>Name</th>
<th>Source</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMG-317</td>
<td>Human</td>
<td>IL-4Rα</td>
</tr>
<tr>
<td>Pitrakinra</td>
<td>Mutein</td>
<td>IL-4Rα</td>
</tr>
<tr>
<td>CAT-354</td>
<td>Human</td>
<td>IL-13</td>
</tr>
<tr>
<td>Lebrikizumab</td>
<td>Humanized</td>
<td>IL-13</td>
</tr>
<tr>
<td>QAX-576</td>
<td>Human mAb</td>
<td>IL-13</td>
</tr>
<tr>
<td>IL-13E13K</td>
<td>Mutein</td>
<td>IL-13</td>
</tr>
<tr>
<td>GM1E7</td>
<td>Mouse mAb</td>
<td>IL-13α1</td>
</tr>
</tbody>
</table>

*Reference 32. mAb, monoclonal antibody; IL, interleukin; R, receptor.
receptor, or affecting the binding of the ligand to the receptor, whereas the ultimate mechanism of novel targeted drugs may be identical to the currently available traditional therapies. Therefore, it is recommended that the focus is shifted from the design of novel molecular targeting drugs to the elucidation of the mechanisms underlying tumor occurrence, development and metastasis, which, in itself, may lead to the overcoming of several problems.

Acknowledgements

This study was supported by Shanghai Young Doctor Training Plan.

References


